Intravenous Infusions (XGHA:IIL) Cash Flow from Financing: GHS0.00 Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Intravenous Infusions Cash Flow from Financing?

Intravenous Infusions XGHA:IIL +8.86% Cash Flow from Financing is GHS0.00 Mil as of . 20.

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in . 20, Intravenous Infusions paid GHS0.00 Mil more to buy back shares than it received from issuing new shares. It received GHS0.00 Mil from issuing more debt. It paid GHS0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received GHS0.00 Mil from paying cash dividends to shareholders. It received GHS0.00 Mil on other financial activities. In all, Intravenous Infusions spent GHS0.00 Mil on financial activities for the six months ended in . 20.

Intravenous Infusions  (XGHA:IIL) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Intravenous Infusions's issuance of stock for the six months ended in . 20 was GHS0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Intravenous Infusions's repurchase of stock for the six months ended in . 20 was GHS0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Intravenous Infusions's net issuance of debt for the six months ended in . 20 was GHS0.00 Mil. Intravenous Infusions received GHS0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Intravenous Infusions's net issuance of preferred for the six months ended in . 20 was GHS0.00 Mil. Intravenous Infusions paid GHS0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Intravenous Infusions's cash flow for dividends for the six months ended in . 20 was GHS0.00 Mil. Intravenous Infusions received GHS0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Intravenous Infusions's other financing for the six months ended in . 20 was GHS0.00 Mil. Intravenous Infusions received GHS0.00 Mil on other financial activities.

Intravenous Infusions Cash Flow from Financing Related Terms

Intravenous Infusions Cash Flow from Financing Historical Data

* Premium members only.

The historical data trend for Intravenous Infusions's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intravenous Infusions Cash Flow from Financing Chart

Intravenous Infusions Annual Data
Trend
Cash Flow from Financing

Intravenous Infusions Semi-Annual Data
Cash Flow from Financing

Intravenous Infusions Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Intravenous Infusions's Cash from Financing for the fiscal year that ended in . 20 is calculated as:

Cash Flow from Financing(A: . 20 )
=Issuance of Stock+Repurchase of Stock+Net Issuance of Debt+Net Issuance of Preferred Stock+Cash Flow for Dividends+Other Financing
=+++++
=0.00

Intravenous Infusions's Cash from Financing for the quarter that ended in . 20 is:

Cash Flow from Financing(Q: . 20 )
=Issuance of Stock+Repurchase of Stock+Net Issuance of Debt+Net Issuance of Preferred Stock+Cash Flow for Dividends+Other Financing
=+++++
=0.00

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Financing for the trailing twelve months (TTM) ended in . 20 was GHS0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Financing of GHS0.00 Mil mean?
Intravenous Infusions (XGHA:IIL) has a Cash Flow from Financing of GHS0.00 Mil as of . 20. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Intravenous Infusions and its competitors.
Is Intravenous Infusions' Cash Flow from Financing too high?
Intravenous Infusions' current Cash Flow from Financing is GHS0.00 Mil.
How does Intravenous Infusions' Cash Flow from Financing compare to PTLF and PCYN?
Intravenous Infusions' Cash Flow from Financing of GHS0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Intravenous Infusions and its competitors. Intravenous Infusions's current Cash Flow from Financing is GHS0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Cash Flow from Financing of GHS0.00 Mil. The current Cash Flow from Financing is GHS0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Cash Flow from Financing is GHS0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intravenous Infusions Business Description

Address Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.